Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)

May 16, 2024 | Press Releases

-Phio’s lead candidate, PH-762, targets PD-1, a critical target in cutaneous carcinomaMARLBOROUGH, Mass., May 16, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™...

Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study

May 15, 2024 | Press Releases

-PH-762 is Phio’s lead product candidate -Screening on the next cohort is on-going MARLBOROUGH, Mass., May 15, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA...

Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update

May 9, 2024 | Press Releases

-Four sites across the country participating in Phase 1b clinical trial for lead product candidate PH-762 -Three patients have been enrolled MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage...

Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)

Apr 30, 2024 | Press Releases

-Phio’s lead clinical product candidate, PH-762, is the focus of dermatological poster presentationMARLBOROUGH, Mass., April 30, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary...

Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells

Apr 22, 2024 | Press Releases

-Injection in murine tumors shows the compound is well tolerated -Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) — Phio...